AbCellera Biologics Inc. Cash Flow Statement
ABCL / Health Care|7 years of annual SEC 10-K data (FY2019-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
AbCellera Biologics Inc. used $131M in operating cash flow and negative free cash flow of $174M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.93 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income | -$146.4M | -$162.9M | -$146.4M | $158.5M | -$2.2M | $118.9M | -$2.2M |
| Depreciation & Amortization | $18.4M | $12.5M | $12.8M | $9.0M | $1.6M | $2.3M | $1.6M |
| Operating Cash Flow | -$131.3M | -$108.6M | -$43.9M | $277.4M | $2.7M | $22.7M | $2.7M |
| Capital Expenditures | $42.8M | $78.4M | $76.9M | $70.7M | $4.0M | $9.7M | $4.0M |
| Free Cash Flow | -$174.1M | -$187.0M | -$120.8M | $206.7M | -$1.3M | $13.0M | -$1.3M |
| FCF Margin | -231.7% | -648.4% | -317.8% | 42.6% | -11.2% | 5.6% | -11.2% |